Hansa Biopharma (Sweden) Today
| HNSA Stock | SEK 27.88 0.08 0.29% |
Performance0 of 100
| Odds Of DistressOver 57
|
Hansa Biopharma is selling for under 27.88 as of the 24th of April 2024; that is -0.29 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 27.2. Hansa Biopharma has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Hansa Biopharma AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 52.44 M outstanding shares. More on Hansa Biopharma AB
Moving together with Hansa Stock
| 0.73 | GENO | Genovis AB | PairCorr |
Moving against Hansa Stock
| 0.65 | EGTX | Egetis Therapeutics | PairCorr |
| 0.54 | XSPRAY | XSpray Pharma AB | PairCorr |
| 0.5 | BINV | BioInvent International | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Hansa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hansa Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hansa Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Soeren Tulstrup |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Hansa Biopharma AB (HNSA) is traded on Stockholm Exchange in Sweden and employs 150 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hansa Biopharma's market, we take the total number of its shares issued and multiply it by Hansa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hansa Biopharma AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 52.44 M outstanding shares.
Hansa Biopharma AB has accumulated about 762.73 M in cash with (504.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.06.
Check Hansa Biopharma Probability Of Bankruptcy
Ownership AllocationHansa Biopharma AB has a total of 52.44 Million outstanding shares. 30% of Hansa Biopharma AB outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hansa Ownership Details
Hansa Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Hansa Biopharma jumping above the current price in 90 days from now is about 91.54%. The Hansa Biopharma AB probability density function shows the probability of Hansa Biopharma stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Hansa Biopharma AB has a beta of -0.5802. This usually indicates as returns on the benchmark increase, returns on holding Hansa Biopharma are expected to decrease at a much lower rate. During a bear market, however, Hansa Biopharma AB is likely to outperform the market. Additionally, hansa Biopharma AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Hansa Biopharma to move above the current price in 90 days from now is about 91.54 (This Hansa Biopharma AB probability density function shows the probability of Hansa Stock to fall within a particular range of prices over 90 days) .
Hansa Biopharma AB Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Hansa Biopharma market risk premium is the additional return an investor will receive from holding Hansa Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Hansa Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Hansa Biopharma's alpha and beta are two of the key measurements used to evaluate Hansa Biopharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.58 | |||
| Standard Deviation | 3.93 | |||
| Variance | 15.45 | |||
| Risk Adjusted Performance | (0.02) |
Hansa Stock Against Markets
Picking the right benchmark for Hansa Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Hansa Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Hansa Biopharma is critical whether you are bullish or bearish towards Hansa Biopharma AB at a given time. Please also check how Hansa Biopharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hansa Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Hansa Biopharma Corporate Directors
Hansa Biopharma corporate directors refer to members of a Hansa Biopharma board of directors. The board of directors generally takes responsibility for the Hansa Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Hansa Biopharma's board members must vote for the resolution. The Hansa Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Birgit Norinder | Independent Director | Profile | |
| Mats Blom | Director | Profile | |
| Andreas Eggert | Independent Director | Profile | |
| Anders Pedersen | Independent Director | Profile |
How to buy Hansa Stock?
Before investing in Hansa Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Hansa Biopharma. To buy Hansa Biopharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Hansa Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Hansa Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Hansa Biopharma AB stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Hansa Biopharma AB stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Hansa Biopharma AB, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Hansa Biopharma AB?
The danger of trading Hansa Biopharma AB is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Hansa Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Hansa Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Hansa Biopharma AB is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Hansa Stock analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |